NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of “Moderate Buy” from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has received an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $48.60.

NAMS has been the topic of several recent research reports. Truist Financial initiated coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Needham & Company LLC lifted their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th.

NewAmsterdam Pharma Trading Down 1.8%

NAMS opened at $30.95 on Thursday. The stock has a market capitalization of $3.62 billion, a P/E ratio of -17.29 and a beta of 0.07. NewAmsterdam Pharma has a 12 month low of $17.63 and a 12 month high of $42.21. The firm’s fifty day simple moving average is $33.52 and its 200 day simple moving average is $33.88.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The company had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. On average, equities research analysts predict that NewAmsterdam Pharma will post -1.78 EPS for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director Louis G. Lange sold 44,619 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total value of $1,357,309.98. Following the sale, the director directly owned 10,360 shares in the company, valued at approximately $315,151.20. The trade was a 81.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 12.74% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC increased its stake in shares of NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares during the last quarter. KBC Group NV acquired a new position in shares of NewAmsterdam Pharma during the 1st quarter worth about $37,000. Navalign LLC acquired a new position in shares of NewAmsterdam Pharma during the 4th quarter worth about $46,000. Finally, AdvisorNet Financial Inc acquired a new position in shares of NewAmsterdam Pharma during the 1st quarter worth about $82,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.